U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H18ClN.ClH
Molecular Weight 296.235
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOBENZOREX HYDROCHLORIDE

SMILES

Cl.C[C@@H](CC1=CC=CC=C1)NCC2=C(Cl)C=CC=C2

InChI

InChIKey=ASTCUURTJCZRSC-ZOWNYOTGSA-N
InChI=1S/C16H18ClN.ClH/c1-13(11-14-7-3-2-4-8-14)18-12-15-9-5-6-10-16(15)17;/h2-10,13,18H,11-12H2,1H3;1H/t13-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H18ClN
Molecular Weight 259.774
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9987865 | https://www.ncbi.nlm.nih.gov/pubmed/9050090

Clobenzorex is a central stimulant and sympathomimetic used as an anti-obesity drug; an n-substituted amphetamine, which is metabolized to amphethamine. Its actions are like those of dexamphetamine and has been used as a drug of abuse.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ASENLIX

Approved Use

Clobenzorex is a stimulant drug of the phenethylamine and amphetamine chemical classes used as an appetite suppressant. This medication is used in obesity.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.777 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBENZOREX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.429 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBENZOREX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17.777 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBENZOREX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.076 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBENZOREX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.002 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBENZOREX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.118 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBENZOREX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
210 mg 3 times / day multiple, oral
Higher than recommended
Dose: 210 mg, 3 times / day
Route: oral
Route: multiple
Dose: 210 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Congestive cardiomyopathy...
AEs leading to
discontinuation/dose reduction:
Congestive cardiomyopathy
Sources:
90 mg single, oral
Highest studied dose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
AEs

AEs

AESignificanceDosePopulation
Congestive cardiomyopathy Disc. AE
210 mg 3 times / day multiple, oral
Higher than recommended
Dose: 210 mg, 3 times / day
Route: oral
Route: multiple
Dose: 210 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Benfluorex and unexplained valvular heart disease: a case-control study.
2010-04-12
Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.
2010-03
Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice.
2006-04
Amphetamine-like stimulant cessation in an abusing patient treated with bupropion.
2004-01
Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results.
2002-05
Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.
2002-04
Amphetamine, clobenzorex, and 4-hydroxyclobenzorex levels following multidose administration of clobenzorex.
2001-04
Clobenzorex: evidence for amphetamine-like behavioral actions.
1997-02
Patents

Sample Use Guides

30 mg bid.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:48:52 GMT 2025
Edited
by admin
on Mon Mar 31 18:48:52 GMT 2025
Record UNII
BC6X5MB664
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOBENZOREX HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
CLOBENZOREX HYDROCHLORIDE [MI]
Preferred Name English
CLOBENZOREX HCL
Common Name English
BENZENEETHANAMINE, N-((2-CHLOROPHENYL)METHYL)-.ALPHA.-METHYL-, HYDROCHLORIDE, (S)-
Systematic Name English
(+)-N-(2-CHLOROBENZYL)-.ALPHA.-METHYLPHENETHYLAMINE HYDROCHLORIDE
Systematic Name English
Clobenzorex hydrochloride [WHO-DD]
Common Name English
CLOBENZOREX HYDROCHLORIDE [MART.]
Common Name English
Code System Code Type Description
FDA UNII
BC6X5MB664
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
MERCK INDEX
m3627
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY Merck Index
EVMPD
SUB01345MIG
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
CAS
5843-53-8
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
EPA CompTox
DTXSID0046145
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
MESH
C000490
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
DRUG BANK
DBSALT002797
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
PUBCHEM
71314913
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
RXCUI
236205
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY RxNorm
SMS_ID
100000087932
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
ECHA (EC/EINECS)
227-434-5
Created by admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY